Introduction
============

Malignant tumors in middle and late stages are generally associated with poor outcomes. Existing studies have suggested that angiogenesis is a key requirement for malignant tumor growth and metastasis.[@b1-ott-11-6119] Tumor angiogenesis is mainly achieved through the VEGF-VEGFR signaling pathway. The combination of vascular endothelial growth factor (VEGF) with vascular endothelial generated factor receptor 2 (VEGFR-2), induces automatic phosphorylation of the VEGFR-2 carboxyl terminal and phosphorylated kinase insert area, thus promoting a downstream signal cascade reaction, which in turn causes changes in vasodilation, distortion and permeability, and promotes tumor angiogenesis.[@b2-ott-11-6119] Anti-angiogenesis targeted drugs can normalize tumor angiogenesis before the vessel fading by improving the blood density, expansion and seepage, and enhance the penetration of chemotherapeutic agents and oxygen supply in a short time to increase the sensitivity to chemoradiation.[@b3-ott-11-6119] In recent years, major advances have been made in immunotherapy; the combination of antiangiogenic drugs and checkpoint blockers have become an attractive strategy in anti-tumor therapy.[@b4-ott-11-6119] Normalization of the tumor vasculature can also reduce the immunosuppression exerted by Tregs and regulatory B cells. Moreover, this normalization can promote anti-tumor immunity by enhancing the uptake of antigen presentation in dendritic cells and activation of M1-associated macrophages and CD8+ cytotoxic T cells.[@b5-ott-11-6119] Currently, anti-tumor angiogenesis drugs targeting the VEGF-VEGFR pathway achieve satisfactory clinical efficacy. For example, bevacizumab is a monoclonal antibody (mAb) that binds to VEGF and it has been approved for first- or second-line treatment in metastatic colorectal cancer and ramucirumab, as a novel human IgG1 mAb, selectively inhibits VEGFR2 and has been clinically used as second-line treatment for advanced or metastatic gastric and gastroesophageal cancer. In addition, sunitinib, sorafenib, etc. are also considered to be part of anti-vascular treatment in clinical practice.[@b6-ott-11-6119]

Apatinib (Aitan^®^, Hengrui Medicine, Lianyungang City, China) is a new type of small molecule tyrosine kinase inhibitor that mainly acts on VEGFR-2.[@b2-ott-11-6119] Its clinical efficacy in advanced gastric cancer has been approved by the China Food and Drug Administration (CFDA) for patients with metastatic gastric adenocarcinoma or gastroesophageal conjunctive adenocarcinoma after the failure of second-line therapy.[@b7-ott-11-6119] Several clinical studies have shown that short-term curative effects and survival benefits for patients with various types of middle−late solid tumor are obviously improved.[@b8-ott-11-6119] Nevertheless, most of the relevant studies are retrospectively non-randomized controlled trials with small sample sizes and uncontrolled statistical analysis, and so far, there has been no assessment of the clinical efficacy of apatinib in advanced solid tumors based on a large sample of RCTs. This paper aims to analyze the efficacy and safety of the therapy with or without apatinib among adult patients with certain types of solid cancers.

Materials and methods
=====================

Literature search
-----------------

We searched PubMed, Cochrane Library, Web of Science, EMBASE, and the CNKI database for articles published from the initiation of each database up to January 1, 2018. All articles were written in English. The key word used in the searches was "Apatinib."

A total of 844 papers were collected. Finally, seven studies with 800 patients, were included after screening. Disagreements were discussed with a third arbiter until a consensus was reached.

Criteria for inclusion and exclusion
------------------------------------

The meta-analysis inclusion criteria were as follows:

1\) randomized controlled trial; 2) patients with a malignant solid tumor diagnosed and confirmed by cytology and pathology, TNM \> III or failed first-line therapy, and with an expected survival time \>1 month; 3) the main intervention measures of the experimental group and the control group were consistent with the use of apatinib; 4) reported the outcome indexes of interest, including short-time efficacy which was assessed by Response Evaluation Criteria In Solid Tumors (RECIST), survival analysis and adverse reactions; 5) high quality studies, newer publications and those with clearly reported data were selected preferentially among similar studies.

The exclusion criteria were as follows: 1) non-randomized controlled trial; 2) repeated publication of data; 3) number of cases \<20; 4) the data was reported too vaguely to be extracted; 5) the outcome index was not reasonable or could not be merged.

Data extraction and quality assessment
--------------------------------------

The titles and abstracts of potentially relevant studies were independently screened by two reviewers according to the predefined selection criteria. Cochrane bias risk assessment criteria were used to evaluate the methodological quality of the RCTs,[@b9-ott-11-6119] which were categorized into a low, unclear, or high risk of bias. This categorization was done according to the risk of bias for each important outcome within the included trials, including adequacy of the generation of allocation sequence, allocation concealment, blinding, and the presence of incomplete outcome data, selective outcome, or other sources of bias. Any disagreement was resolved through discussion and consensus with a third author. The extracted data were summarized as follows: authors, publication time, number of cases, basic information about the patients, intervention measures and outcome indicators.

Statistical analysis
--------------------

Stata12.0 statistical software was used for meta-analysis and publication bias testing. The dichotomous data of the disease control rate (DCR), objective response rate (ORR) and adverse reactions were statistically based on Risk Ratio (RR), while survival data, including PFS, OS were based on Hazard Ratio (HR). The 95% confidence interval (CI) was calculated as a measure of estimate uncertainty. Heterogeneity was evaluated according to the sampling frame and statistical tests, which included chi-squared and *I*^2^ statistics; heterogeneity was considered low, moderate, or high for *I*^2^ values under 25%, between 25% and 50% and over 50%, respectively.[@b10-ott-11-6119] The heterogeneity was judged according to clinical thinking. Finally, we conducted a simple assessment by sensitivity analysis and evaluation of publication bias, and the credibility of our research was confirmed.

Results
=======

Search results and quality evaluation
-------------------------------------

A total of 844 relevant papers were retrieved from five databases (PubMed, Cochrane Library, Web of Science, Embase and CNKI). The titles and abstracts were screened by two authors (JS and HL) respectively. Consequently, studies including case reports, non-randomized controlled trials, repetitive articles, and those containing the same set of published data were eliminated. Finally, seven trials were found to match the inclusion criteria and were included in the analysis.[@b11-ott-11-6119]--[@b17-ott-11-6119] A flow chart of the search process is shown in [Figure 1](#f1-ott-11-6119){ref-type="fig"}. Cochrane bias risk assessment criteria were then used to evaluate the methodological quality of the RCTs; any disagreement was resolved through discussion and consensus with a third author (JX). The quality of each trial is shown in [Figure 2](#f2-ott-11-6119){ref-type="fig"}.

General characteristics of the included studies
-----------------------------------------------

All the included studies were RCTs which contained similar general characteristics of patients diagnosed with one of the three tumor types, commonly found in China: gastric cancer, hepatocellular carcinoma and non-small-cell lung cancer. Consequently, an additional article[@b18-ott-11-6119] including patients with malignant ascites was excluded since the heterogeneity was greater when considering non-solid tumors. Meta-analysis was performed based on random-effect models considering heterogeneity from tumor type, drug dose, application line, and so forth.

The patients were almost all ethnic Chinese, and there was a similar number of male and female patients. For the intervention, the treatment with or without apatinib was the main difference, while apatinib dose, treatment line and tumor type were also analyzed. The primary outcomes referred to short efficacy and survival time of the patient. Basic information about the articles is shown in [Table 1](#t1-ott-11-6119){ref-type="table"}.

Short-term efficacy: ORR and DCR
--------------------------------

Seven studies that included 800 patients were used to evaluate the short-time efficacy. They contained ORR and DCR of apatinib on advanced solid cancers, including gastric cancer, hepatocellular carcinoma and non-small-cell lung cancer. Briefly, a significantly higher ORR and DCR were observed in the apatinib groups than in control groups (RR=2.18, 95% CI: 1.30--3.65; and RR=2.09, 95% CI: 1.21--3.60, respectively) (shown in [Figure 3A and B](#f3-ott-11-6119){ref-type="fig"}). Furthermore, although no significant heterogeneity between studies was found in ORR (*I*^2^=0%, *P*=0.542), we performed subgroup analysis on the cancer types in light of their clinical differences. Surprisingly, the subgroup analysis suggested that there was no statistically significant difference in ORR between the apatinib and the control group (GC: RR=7.22, 95% CI: 0.96--54.32; HCC: RR=1.76, 95% CI: 0.96--3.22; NSCLC: RR=3.14, 95% CI: 1.00--9.86). In addition, according to an analysis based on apatinib's different application stages, a difference in ORR between its third-line application (RR=8.49, 95% CI: 8.49--1.65) and second-line application (RR=2.43, 95% CI: 2.43--0.69) was observed. Compared with the control group, the third-line application of apatinib increased ORR (*P*\<0.05), while the second-line application appeared to have no significant benefit. The same results were also seen in DCR (third line: RR=3.39, 95% CI: 2.32--4.95; second line: RR=1.28, 95% CI: 0.60--2.76). Moreover, the stratified analysis of the dose of apatinib indicated that the doses of 850 mg qd and 750 mg qd had a higher DCR than did the control group (*P*\<0.05); but the dose of 500 mg qd seemed to have no effect (95% CI: 0.79--2.46) (shown in [Table 2](#t2-ott-11-6119){ref-type="table"}).

PFS
---

Overall, apatinib prolonged the patients' PFS (HR=0.38, 95% CI: 0.28--0.52) (shown in [Figure 3C](#f3-ott-11-6119){ref-type="fig"}). Furthermore, we performed subgroup analysis of the tumor type based on the application stage and the dose of apatinib used. Our data showed that apatinib extended the patients' mean PFS for gastric cancer (HR=0.29, 95% CI: 0.12--0.71) and NSCLC (HR=0.40, 95% CI: 0.27--0.58); nevertheless, there was not enough data to support these same conclusions in hepatocellular carcinoma. In addition, the third-line application of apatinib further reduced the risk ratio in patients (HR=0.30, 95% CI: 0.18--0.50 in third line; HR=0.48, 95% CI: 0.33--0.70 in second line). The dose of 750 mg qd and 850 mg qd of apatinib have been shown to be more efficient in improving PFS than was the dose of 500 mg qd or lower (shown in [Table 3](#t3-ott-11-6119){ref-type="table"}).

OS
--

Apatinib prolonged the OS of patients. Three of the included articles indicated that the apatinib group had a 0.5 times higher OS than did that of the control group (HR=0.54, 95% CI: 0.35--0.81) (shown in [Figure 3D](#f3-ott-11-6119){ref-type="fig"}).

Adverse reactions
-----------------

In this paper, we analyzed short-term acute adverse reactions, such as myelosuppression, nausea and vomiting, hypertension, proteinuria, hand-foot syndrome, and gastrointestinal reactions. The results showed that the apatinib group had a significantly higher incidence of hypertension (RR=8.38, *P*\<0.05), urine protein (RR=2.66, *P*\<0.05), hand foot syndrome (RR=11.50, *P*\<0.05), and gastrointestinal reaction (diarrhea) (RR=2.63, *P*=0.02); while no difference in bone marrow suppression, nausea and vomiting were found compared to the control group ([Table 4](#t4-ott-11-6119){ref-type="table"}). As defined in the original literature, most adverse reactions are classified below level 2 (according to Common Terminology Criteria for Adverse Events).

Publication bias assessment and sensitivity analyses
----------------------------------------------------

Because of the limited number of clinical studies included (n\<10), we did not perform a statistical evaluation of publication bias. For sensitivity analyses, we tried to perform an analysis of each outcome indicator after excluding each article and doing the statistical analysis again by including an article which was excluded before. It was found that the excluded results did not differ from the previous ones ([Table 5](#t5-ott-11-6119){ref-type="table"}), suggesting that the sensitivity was low; and the results were robust and credible.

Discussion
==========

In this article, we compared the efficacy and safety of apatinib in patients with various types of advanced malignant solid tumors. First, compared with the control group, the apatinib group showed significant improvements in ORR and DCR. Moreover, the third-line application seemed to have better benefits compared to second-line treatment, which suggests that apatinib could be used as a new treatment option for patients with advanced GC, HPC, and NSCLC who failed to respond to second-line treatment. With reference to the heterogeneity among the studies; the cancer types, dosage and application stages of apatinib were initially analyzed. The stratification of the clinical data related to each kind of tumor showed high heterogeneity (*I*^2^\>50%, *P*\<0.1). Consequently, we conducted a regression analysis of the apatinib dose used in the experimental groups; the specific dosage of apatinib, ie, 850 mg qd, 750 mg qd and 500 mg qd were investigated in five articles (it should be noted that in the 500 mg qd group, the apatinib dose was appropriately reduced when the adverse reactions were not tolerable). Briefly, our data showed that the heterogeneity was significantly decreased in each group (850 mg group: *I*^2^=0.00, *P*=0.47; 500 mg group: *I*^2^=53%, *P*=0.14; only one group of clinical data was included in the 700 mg group). In addition, logRR and the increased dosage showed an inversion proportion, and after the dosage was included as a covariate, T-squared was reduced from 0.5625 to 0.0023, indicating that the dosage was an important cause of heterogeneity, accounting for 99.08%. Through the analysis of the included literature, it was shown that the dose of 850 mg was the most beneficial for the short-term efficacy.

According to this literature review, we believe that apatinib shows a satisfactory short-term effect because of the time window of vascular normalization caused by the prophase application of apatinib. Tumor angiogenesis is different from normal blood vessels in structure and function, and it creates a tumor microenvironment characterized by high interstitial fluid pressure (IFP), hypoxia and acidosis in tissues, which in turn affects the curative effect and prognosis of the tumor.[@b19-ott-11-6119] Anti-angiogenesis targeted drugs can normalize angiogenesis before the tumor vessels regressing, by improving the blood density, expansion and seepage, which enhance the penetration of chemotherapeutic agents and oxygen supply in a short time, thus increasing tumor sensitivity to chemoradiation.[@b3-ott-11-6119]

In terms of safety, this analysis was mainly focused on investigating the main adverse reactions of apatinib in clinical reports, such as bone marrow suppression (mainly leukopenia), hypertension, proteinuria, extremities syndromes, digestive tract reactions, etc. Like most other targeted drugs, the patients in the apatinib groups showed no significant difference in bone marrow suppression, nausea and vomiting compared with the control group but did experience induced hypertension, proteinuria and hand-foot syndrome. The specific mechanisms causing adverse reactions are unknown. Some studies have shown that VEGFR receptor inhibitors reduce the synthesis of NO and prostacyclin by inhibiting the VEGFR of endothelial cells,[@b20-ott-11-6119] leading to elevated blood pressure. Furthermore, the occurrence of proteinuria may be associated with inhibition of VEGF of the foot and the vascular cells surrounding tubular cells.[@b21-ott-11-6119] A retrospective cohort study showed that most of the adverse reactions occurred in the first cycle of the apatinib treatment. On the other hand, the risk of death was reduced by 10%, if the adverse events occurred one week earlier each additional adverse event reduced the risk of death by 23%.[@b22-ott-11-6119] The original studies included in the meta-analysis, reported that most adverse reactions were grade 1 or grade 2 and were controllable. These data further suggest that it is possible to predict the curative effect by a series of mathematical conversions related to the adverse reactions that occur in the short term, which is beneficial for the exploration of the molecular markers of anti-vascular drugs. In addition, the author observed that there are some other adverse reactions, such as hemorrhagic cystitis and dyspnea, which can be improved by reduced dose administration and symptomatic treatment.

Preliminary analysis showed that the PFS in patients with advanced tumors was extended by apatinib (HR=0.38, 95% CI: 0.28, 0.52). Statistically, no significant differences in PFS were found among five of the studies included in this meta-analysis. In consideration of the clinical-related heterogeneity of each cancer type and the dosage and application stages of apatinib, we performed a subgroup analysis and once again, found no significant difference between studies. A total of three eligible articles were used to evaluate the patient's OS. The meta-analysis suggested that the apatinib treatment can also prolong the patient's OS, but the heterogeneity between studies could not be explained due to a lack of data.

Overall, multiple clinical reports have shown that apatinib has a certain effect on advanced liver cancer,[@b23-ott-11-6119] lung cancer,[@b24-ott-11-6119] ovarian cancer,[@b25-ott-11-6119] and other types of malignancy. Nonetheless, there is no clinical research involving a large dataset that reveals its efficacy in malignant solid tumors. In this study, we performed a statistical analysis of the short-term effects, survival benefit and acute adverse reactions of apatinib in seven clinical studies and 800 patients. Because of the great achievements made in the field of immunotherapy, the combination of antiangiogenic drugs and checkpoint blockers has become an attractive strategy in anti-tumor therapy. Apatinib is a new type of small molecule tyrosine kinase inhibitor of VEGFR with a mechanism similar to that of ramucirumab, which has been approved by the Food and Drug Administration as a second-line treatment of advanced or metastatic gastric or gastroesophageal cancer. Apatinib can be combined with immunotherapy thus providing more treatment choices for patients.

The major limitations of this study are as follows: 1) here are not enough data for an in-depth analysis of PFS and OS; more clinical data are necessary to support the survival benefit of apatinib; 2) the current clinical study is limited to the Asian population, so whether the treatment effect of apatinib is different in other populations needs to be further investigated. ANGEL[@b26-ott-11-6119] is an RCT study that is currently evaluating the efficacy and safety of apatinib in the treatment of advanced gastric cancer in North America, Europe and the subPacific, and its results are worth looking forward to; 3) among all the studies including combined apatinib with chemotherapy, we could not perform a subgroup analysis by chemotherapy drugs because of the limited number of studies, and this does not even include the other types of anti-tumor drugs that were used. The existing experimental results show that in the environment of tumor malnutrition induced by apatinib, the combination with Elemene Injections can induce protective autophagy and prevent human hepatoma cancer cells from undergoing apoptosis[@b27-ott-11-6119] which suggests they should not be used concurrently.

Conclusion
==========

In conclusion, the anti-tumor angiogenesis targeted drug apatinib shows a significant therapeutic effect in advanced solid tumors (gastric carcinoma, hepatocellular carcinoma and non-small-cell lung cancer), with controllable adverse effects. However, the present research has shown that even in the case of apatinib's most common application for stomach cancer, the following limitations still exist in the literature: the details of early chemotherapy regimens are unclear; the analysis of predictive factors, and the ability to perform subgroup analysis. Therefore, more clinical studies on apatinib are required.
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###### 

Meta-analysis of the short-term efficacy and survival benefit of apatinib.

**Notes:** (**A**) DCR; (**B**) ORR; (**C**) PFS; and (**D**) OS. Weights are from random-effects analysis.

**Abbreviations:** DCR, disease control rate; ORR, objective response rate; PFS, progression-free survival; OS, overall survival.
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###### 

Basic information regarding the studies

  Study                            Year   Tumor type                               N     M/F ratio   Region   Participants            Line of apatinib                         Outcome index   
  -------------------------------- ------ ---------------------------------------- ----- ----------- -------- ----------------------- ---------------------------------------- --------------- ----------------------------------------------------------------------------------------------------------------
  Li et al[@b11-ott-11-6119]       2013   Gastric cancer                           144   109:33      China    Placebo                 Apatinib (850 mg qd or 425 mg bid)       Third line      ORR, DCR, PFS and OS, adverse reaction
  Li et al[@b16-ott-11-6119]       2017   Hepatocellular carcinoma                 40    --          China    TACE                    Oral apatinib (unknown dose)             Unknown         CR, PR, SD, PD, survival rate of half year/1 year, total survival rate, VEGF and MMP-9 level, adverse reaction
  Lu et al[@b15-ott-11-6119]       2017   Hepatocellular carcinoma                 44    33:9        China    TACE                    Oral apatinib (500 mg qd) + TACE         Unknown         AFP level, ORR, PFS, adverse reaction
  Guo and Jing[@b14-ott-11-6119]   2017   Nonsquamous non-small-cell lung cancer   39    20:19       China    Received chemotherapy   Oral apatinib (500 mg qd) + docetaxel    Second line     PFS, DCR, ORR, adverse reaction
  Wang et al[@b13-ott-11-6119]     2017   Nonsquamous non-small-cell lung cancer   128   87:41       China    Received chemotherapy   Apatinib + chemotherapy (unknown dose)   Second line     PFS, OS, CR, PR, SD, PD, adverse reaction
  Zhang et al[@b12-ott-11-6119]    2012   Nonsquamous non-small-cell lung cancer   135   --          China    Placebo                 Apatinib (750 mg qd)                     Third line      CR, PR, SD, PD, PFS, adverse reaction
  Li et al[@b17-ott-11-6119]       2016   Gastric cancer                           273   201:66      China    Placebo                 Apatinib (850 mg qd)                     Third line      CR, PR, SD, PD, OS, PFS, adverse reaction

**Abbreviations:** ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; CR, complete remission; PR, partial remission; SD, stable disease; PD, progression disease; AFP, alpha fetoprotein.

###### 

Subgroup analysis of DCR

  Subgroup analysis   Total no of studies   Treatment group   Control group   RR (95% CI) of DCR        
  ------------------- --------------------- ----------------- --------------- -------------------- ---- -------------------
  **Tumor type**                                                                                        
  GC                  2                     309               114             144                  13   4.10 (2.39, 7.02)
  HCC                 2                     40                27              42                   20   1.54 (0.66, 3.60)
  NSCLC               3                     137               85              141                  51   1.71 (0.81, 3.60)
  **Line**                                                                                              
  Second line         2                     47                23              96                   40   1.28 (0.60, 2.76)
  Third line          3                     399               176             189                  24   3.39 (2.42, 4.95)
  **Apatinib dose**                                                                                     
  850 mg              2                     309               114             144                  13   4.10 (2.39, 7.02)
  750 mg              1                     90                62              45                   11   2.82 (1.66, 4.80)
  500 mg              2                     40                29              42                   22   1.40 (0.79, 2.46)

**Abbreviations:** CR, complete remission; PR, partial remission; SD, stable disease; DCR, disease control rate; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer.

###### 

Subgroup analysis of PFS

  Subgroup analysis   Total no of studies   Total no of patients   HR of apatinib   95% CI
  ------------------- --------------------- ---------------------- ---------------- ------------
  **Tumor type**                                                                    
  GC                  2                     414                    0.29             0.12, 0.71
  HCC                 2                     44                     0.61             0.27, 1.39
  NSCLC               3                     302                    0.4              0.27, 0.58
  **Line**                                                                          
  Second line         2                     127                    0.48             0.33, 0.70
  Third line          3                     549                    0.3              0.18, 0.50
  **Apatinib dose**                                                                 
  850 mg              2                     414                    0.29             0.12, 0.71
  750 mg              1                     135                    0.28             0.17, 0.45
  500 mg              2                     83                     0.55             0.32, 0.94

**Note:** See [Figure 3D](#f3-ott-11-6119){ref-type="fig"}.

**Abbreviations:** GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer.

###### 

Adverse reactions of the apatinib group vs the control group

  Adverse reaction      Study no   RR      Min 95% CI   Max 95% CI   *P*-value
  --------------------- ---------- ------- ------------ ------------ -----------
  Myelosuppression      5          1.45    0.52         4.06         0.48
  Nausea and vomiting   3          1.00    0.63         1.58         0.99
  Hypertension          5          8.38    4.89         14.37        \<0.005
  Proteinuria           5          2.66    1.72         4.11         \<0.005
  Hand-foot syndrome    5          11.50   5.68         23.68        \<0.005
  Diarrhea              4          2.63    1.20         5.79         0.016

###### 

The sensitivity analyses of the study

  Sensitivity analyses                      No of studies   RR (95% CI)   HR (95% CI)                                                                                     
  ----------------------------------------- --------------- ------------- ------------------- ----------- ------------------- ----------- ------------------- ----------- -------------------
  Total studies                             7               7 (n=800)     2.09 (1.21, 3.60)   7 (n=800)   2.18 (1.30, 3.65)   6 (n=760)   0.38 (0.28, 0.52)   3 (n=542)   0.54 (0.35, 0.81)
  Liu et al[@b18-ott-11-6119] added         8               8 (n=829)     --                  8 (n=829)   2.16 (1.39, 3.16)   6 (n=760)   0.38 (0.28, 0.52)   3 (n=542)   0.54 (0.35, 0.82)
  Li et al[@b11-ott-11-6119] excluded       6               6 (n=656)     1.97 (1.10, 3.94)   6 (n=656)   2.07 (1.23, 3.50)   5 (n=616)   0.43 (0.35, 0.53)   2 (n=398)   0.67 (0.53, 0.85)
  Li et al[@b16-ott-11-6119] excluded       6               6 (n=760)     2.05 (1.12, 3.74)   6 (n=760)   2.21 (1.22, 3.98)   6 (n=760)   0.38 (0.28, 0.52)   3 (n=542)   0.54 (0.35, 0.81)
  Lu et al[@b15-ott-11-6119] excluded       6               6 (n=756)     2.35 (1.35, 4.09)   6 (n=756)   3.38 (1.47, 7.77)   5 (n=726)   0.36 (0.25, 0.51)   3 (n=542)   0.54 (0.35, 0.81)
  Guo and Jing[@b14-ott-11-6119] excluded   6               6 (n=761)     2.12 (1.31, 3.97)   6 (n=761)   2.08 (1.20, 3.61)   5 (n=727)   0.36 (0.25, 0.52)   3 (n=542)   0.54 (0.35, 0.81)
  Wang et al[@b13-ott-11-6119] excluded     6               6 (n=672)     2.45 (1.31, 4.58)   6 (n=672)   2.22 (1.31, 3.77)   5 (n=632)   0.36 (0.24, 0.53)   2 (n=414)   0.52 (0.27, 0.98)
  Zhang et al[@b12-ott-11-6119] excluded    6               6 (n=665)     1.99 (1.07, 3.72)   6 (n=665)   2.05 (1.21, 3.47)   5 (n=625)   0.41 (0.29, 0.58)   3 (n=542)   0.54 (0.35, 0.82)
  Li et al[@b17-ott-11-6119] excluded       6               6 (n=530)     1.79 (1.10, 2.90)   6 (n=530)   2.11 (1.25, 3.56)   5 (n=490)   0.36 (0.24, 0.55)   2 (n=272)   0.49 (0.25, 0.70)

**Abbreviations:** DCR, disease control rate; ORR, objective response rate; PFS, progression free survival; OS, overall survival.
